Corcept Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CORT and other ETFs, options, and stocks.About CORT
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.
CEOJoseph K. Belanoff
CEOJoseph K. Belanoff
Employees500
Employees500
HeadquartersRedwood City, California
HeadquartersRedwood City, California
Founded1998
Founded1998
Employees500
Employees500
CORT Key Statistics
Market cap7.52B
Market cap7.52B
Price-Earnings ratio61.88
Price-Earnings ratio61.88
Dividend yield—
Dividend yield—
Average volume693.21K
Average volume693.21K
High today$71.99
High today$71.99
Low today$69.03
Low today$69.03
Open price$69.25
Open price$69.25
Volume937.14K
Volume937.14K
52 Week high$117.33
52 Week high$117.33
52 Week low$37.82
52 Week low$37.82
CORT News
Simply Wall St 1d
The Bull Case For Corcept Therapeutics Could Change Following FDA Acceptance of Relacorilant Application – Learn WhyCorcept Therapeutics recently announced that the FDA has accepted its New Drug Application for relacorilant as a potential treatment for patients with platinum-...
TipRanks 7d
Corcept Therapeutics price target raised to $140 from $137 at CanaccordCanaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $140 from $137 and keeps a Buy rating on the shares. The firm met with management and...
TipRanks 7d
Corcept Therapeutics’ New Drug Application Accepted by FDAElevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
People also own
Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.